Pluristem Soars Most in Four Months on Results of Cell Study

Pluristem Therapeutics Inc. (PSTI) surged the most in more than four months after the developer of cell- therapy products said a clinical trial of its PLX-PAD cells to treat critical limb ischemia met all the protocol endpoints.

The shares jumped 11 percent the most since June 20, to 9.92 shekels at 11:41 a.m. in Tel Aviv, giving the Haifa, Israel-based company a market value of 426 million shekels ($116 million).

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.